Cytokine expression profile of dengue patients at different phases of illness
- PMID: 23284941
- PMCID: PMC3527385
- DOI: 10.1371/journal.pone.0052215
Cytokine expression profile of dengue patients at different phases of illness
Abstract
Background: Dengue is an important medical problem, with symptoms ranging from mild dengue fever to severe forms of the disease, where vascular leakage leads to hypovolemic shock. Cytokines have been implicated to play a role in the progression of severe dengue disease; however, their profile in dengue patients and the synergy that leads to continued plasma leakage is not clearly understood. Herein, we investigated the cytokine kinetics and profiles of dengue patients at different phases of illness to further understand the role of cytokines in dengue disease.
Methods and findings: Circulating levels of 29 different types of cytokines were assessed by bead-based ELISA method in dengue patients at the 3 different phases of illness. The association between significant changes in the levels of cytokines and clinical parameters were analyzed. At the febrile phase, IP-10 was significant in dengue patients with and without warning signs. However, MIP-1β was found to be significant in only patients with warning signs at this phase. IP-10 was also significant in both with and without warning signs patients during defervescence. At this phase, MIP-1β and G-CSF were significant in patients without warning signs, whereas MCP-1 was noted to be elevated significantly in patients with warning signs. Significant correlations between the levels of VEGF, RANTES, IL-7, IL-12, PDGF and IL-5 with platelets; VEGF with lymphocytes and neutrophils; G-CSF and IP-10 with atypical lymphocytes and various other cytokines with the liver enzymes were observed in this study.
Conclusions: The cytokine profile patterns discovered between the different phases of illness indicate an essential role in dengue pathogenesis and with further studies may serve as predictive markers for progression to dengue with warning signs.
Conflict of interest statement
Figures



Similar articles
-
Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1β and CCL2/MCP-1 in dengue fever and parvovirosis.Mem Inst Oswaldo Cruz. 2012 Feb;107(1):48-56. doi: 10.1590/s0074-02762012000100007. Mem Inst Oswaldo Cruz. 2012. PMID: 22310535
-
Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity.BMC Infect Dis. 2008 Jun 25;8:86. doi: 10.1186/1471-2334-8-86. BMC Infect Dis. 2008. PMID: 18578883 Free PMC article.
-
Th2-predominant immune response underlies the pathogenesis of Dengue.Cytokine. 2024 May;177:156562. doi: 10.1016/j.cyto.2024.156562. Epub 2024 Mar 1. Cytokine. 2024. PMID: 38430693
-
Cytokine IP-10 and GM-CSF are prognostic biomarkers for severity in secondary dengue infection.Hum Immunol. 2021 Jun;82(6):438-445. doi: 10.1016/j.humimm.2021.03.003. Epub 2021 Mar 23. Hum Immunol. 2021. PMID: 33766427
-
Biomarkers of severe dengue disease - a review.J Biomed Sci. 2015 Oct 14;22:83. doi: 10.1186/s12929-015-0191-6. J Biomed Sci. 2015. PMID: 26462910 Free PMC article. Review.
Cited by
-
Association DENV1 and DENV2 infection with high serum levels of soluble thrombomodulin and VEGF in patients with dengue fever and dengue hemorrhagic fever.Int J Clin Exp Med. 2014 Feb 15;7(2):370-8. eCollection 2014. Int J Clin Exp Med. 2014. PMID: 24600491 Free PMC article.
-
IL-10 and socs3 Are Predictive Biomarkers of Dengue Hemorrhagic Fever.Mediators Inflamm. 2017;2017:5197592. doi: 10.1155/2017/5197592. Epub 2017 Jul 30. Mediators Inflamm. 2017. PMID: 28827898 Free PMC article.
-
Cytokine and chemokine kinetics in natural human dengue infection as predictors of disease outcome.Sci Rep. 2025 May 4;15(1):15612. doi: 10.1038/s41598-025-99628-y. Sci Rep. 2025. PMID: 40320430 Free PMC article.
-
Zika Virus Infection: Current Concerns and Perspectives.Clin Rev Allergy Immunol. 2016 Dec;51(3):383-394. doi: 10.1007/s12016-016-8554-7. Clin Rev Allergy Immunol. 2016. PMID: 27236440 Review.
-
Anti-inflammatory Compound Shows Therapeutic Safety and Efficacy against Flavivirus Infection.Antimicrob Agents Chemother. 2019 Dec 20;64(1):e00941-19. doi: 10.1128/AAC.00941-19. Print 2019 Dec 20. Antimicrob Agents Chemother. 2019. PMID: 31636070 Free PMC article.
References
-
- TDR/WHO (2009) Dengue: guidelines for diagnosis, treatment, prevention and control; World Health O, Special Programme for R, Training in Tropical D, World Health Organization. Department of Control of Neglected Tropical D, World Health Organization E et al., editors. Geneva: World Health Organization.
-
- Webster DP, Farrar J, Rowland-Jones S (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9: 678–687. - PubMed
-
- Halstead SB, Porterfield JS, O’Rourke EJ (1980) Enhancement of dengue virus infection in monocytes by flavivirus antisera. Am J Trop Med Hyg 29: 638–642. - PubMed
-
- Kurane I, Ennis FE (1992) Immunity and immunopathology in dengue virus infections. Semin Immunol 4: 121–127. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous